INV 500
Alternative Names: INV-500Latest Information Update: 03 Jul 2023
At a glance
- Originator INVENT Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus-3C-like-proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 03 Jul 2023 Discontinued - Preclinical for COVID-2019 infections in USA (PO) prior to July 2023 (Invent Pharmaceuticals pipeline, July 2023)
- 30 Nov 2022 Preclinical trials in COVID-2019 infections in USA prior to 30 November 2022 (PO) (Invent Pharmaceuticals pipeline, November 2022)
- 30 Nov 2022 Invent Pharmaceuticals plans a phase II trial for COVID-19 infection (Invent Pharmaceuticals pipeline, November 2022)